Genzyme maintains neutral rating from Merrill

Genzyme Corp. was maintained by Merrill Lynch analyst Eric Ende at its neutral rating on new that the company's Myozyme was approved for Pompe disease, including pediatric disease. The Food and Drug Administration suggested limited clinical trial experience in late-onset (adult) patients, but adult use should occur with this label, generating roughly 8-fold higher revenues than infants. Merrill estimates sales of $35 million in 2006, $105 million in 2007, $154 million in 2008, and peak sales of more than $260 million in 2010. Shares of the Cambridge, Mass., biotechnology company were down $1.74, or 2.85%, at $59.42 on volume of 3,154,015 shares versus the three-month running average of 2,514,220 shares. (Nasdaq: GENZ)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.